DEF: Gossamer Bio Seeks Stockholder Approval for Share Issuance

Gossamer Bio is holding a special meeting to seek stockholder approval for the potential issuance of common stock related to a private placement, including shares for executive officers and directors.

Summary

• Gossamer Bio is convening a Special Meeting of Stockholders on October 27, 2026, to vote on proposals related to a private placement of securities.
• The primary proposal (Proposal No. 1) seeks approval for the potential issuance of common stock upon the exercise of pre-funded warrants and FDA approval warrants, and the conversion of preferred stock.
• This approval is required under Nasdaq Listing Rules 5635(c) and 5635(d) because the potential issuance of shares exceeds 20% of outstanding shares and involves securities for certain executive officers and directors.
• A second proposal (Proposal No. 2) seeks approval to adjourn the meeting if necessary to solicit additional votes for Proposal No. 1.
• The company also implemented a 1-for-80 reverse stock split effective September 10, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it addresses necessary financing and regulatory compliance, but involves potential dilution and requires stockholder approval.

Positives

• The company is proactively addressing Nasdaq listing rule requirements for share issuances.
• The private placement aims to raise approximately $125 million in gross proceeds for the second closing.
• The Board of Directors unanimously recommends voting FOR both proposals, indicating management's support for the transactions.
• Support agreements from existing stockholders representing approximately 23% of outstanding common stock have been secured to vote in favor of the proposals.

Negatives

• The potential issuance of a significant number of shares (over 20%) could lead to dilution for existing stockholders.
• The release of up to approximately 20,086,929 shares of common stock onto the market could adversely affect the trading price.
• The company's use of proceeds is at the discretion of the Board and management, and may not improve operating results or increase investment value.
• If stockholder approval is not obtained, the company's financing and strategic flexibility could be limited, and second closing commitments may terminate if not completed by December 31, 2026.

Risks

• The potential issuance of a large number of shares could dilute existing shareholders' ownership and voting power.
• The release of a significant number of shares into the market could negatively impact the stock's trading price.
• If stockholder approval is not obtained, the company's ability to finance operations and pursue strategic initiatives may be constrained.
• The termination of second closing commitments if not completed by December 31, 2026, poses a risk to the planned capital raise.

Future Outlook

The company is seeking stockholder approval to enable the potential issuance of shares of common stock upon exercise of warrants and conversion of preferred stock, which is crucial for the second closing of the private placement and future financing flexibility. The outcome of the stockholder vote will determine the structure and timing of these issuances and potential capital raises.

Management Comments

• The Board has determined that each of the proposals is in the best interests of the Company and its stockholders and unanimously recommends that you vote FOR each proposal.
• We are asking our stockholders to approve, in accordance with Nasdaq Listing Rules 5635(c) and 5635(d), the potential issuance of shares of Common Stock upon (i) the exercise of the Pre-Funded Warrants issued or issuable pursuant to the Purchase Agreement, (ii) the exercise of the FDA Approval Warrants issuable pursuant to the Purchase Agreement, and (iii) the conversion of shares of the Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock...

Industry Context

StockSavvy.ai notes that seeking stockholder approval for significant share issuances, especially those involving insiders and exceeding 20% thresholds, is a common but critical step for companies listed on Nasdaq. This process is essential for maintaining compliance and facilitating necessary capital raises, particularly for biotechnology companies like Gossamer Bio that often rely on such placements to fund ongoing research and development.

Comparison to Industry Standards

• The requirement for stockholder approval for issuances exceeding 20% of outstanding stock is a standard Nasdaq Listing Rule (5635(d)).
• The requirement for stockholder approval for issuances to officers and directors at below-market prices is also a standard Nasdaq Listing Rule (5635(c)).
• The structure of the private placement, involving pre-funded warrants and milestone-based warrants, is a common financing mechanism in the biotechnology sector to bridge funding gaps and align investor interests with development milestones.
• The reverse stock split is a common corporate action to increase the per-share price of a stock, often to meet exchange listing requirements or improve marketability, though its long-term impact on valuation is debated.

Management Changes

Related Party Transactions

• Certain executive officers and directors of Gossamer Bio, through entities they control, are purchasers in the private placement.
• Faheem Hasnain (CEO) and Bryan Giraudo (CFO/COO) are participating in the private placement.
• Gregory A. Ciongoli, a newly appointed director, is also a purchaser in the private placement.

Stakeholder Impact

• Existing stockholders may experience dilution in their ownership percentage and voting power due to the potential issuance of new shares.
• The potential increase in the number of outstanding shares could lead to a decrease in the market price per share.
• The proceeds from the private placement are intended to fund the company's operations and strategic initiatives, which could benefit all stakeholders if successful.
• The participation of management and directors in the private placement, while requiring stockholder approval, aligns their interests with the company's financing needs.

Next Steps

• Stockholders must vote on Proposal No. 1 (approval of share issuances) and Proposal No. 2 (adjournment) at the Special Meeting.
• If Proposal No. 1 is approved, the company can proceed with the full issuance of shares under the private placement terms.
• If Proposal No. 1 is not approved, the company must resubmit the proposal every 90 days until approval is obtained, and financing and strategic flexibility may be limited.
• The Second Closing is contingent on the FDA accepting the NDA filing for seralutinib in 2026 and other conditions, and must occur by December 31, 2026, for the related warrants to be issued.

Key Dates

Recommendation

The filing details a necessary step for financing and regulatory compliance, but the potential for significant dilution and the uncertainty surrounding the FDA approval for seralutinib warrant a cautious approach. While the company is taking steps to secure funding, the risks associated with share issuance and drug development outcomes suggest a 'hold' recommendation until further clarity emerges.

Keywords

Special Meeting, Proxy Statement, Stockholder Approval, Private Placement, Warrants, Convertible Preferred Stock, Nasdaq Listing Rules, Reverse Stock Split